Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dapagliflozin suppresses hepcidin

Ghanim HA et al. AACE 2018, Abstract 228.

Key clinical point: The SGLT2 inhibitor dapagliflozin suppressed hepcidin, a proinflammatory inhibitor of iron transport.

Major finding: Hepcidin plasma concentration fell from 265 to 215 ng/mL (P < 0.05) in dapagliflozin-treated patients.

Study details: A study of 22 patients with type 2 diabetes randomized to either dapagliflozin 10 mg daily or placebo for 12 weeks.

Disclosures: Dr. Ghanim had no disclosures related to the presentation.

Source: Ghanim HA et al. AACE 2018, Abstract 228.

Read the article.

Citation:

Ghanim HA et al. AACE 2018, Abstract 228.